In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 326 to 350 of 404

TitleTypeExpected publication date
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]Technology appraisal guidanceTBC
Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441Technology appraisal guidanceTBC
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer ID6346Technology appraisal guidanceTBC
Sipavibart for preventing COVID 19 [ID6282]Technology appraisal guidanceTBC
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]Technology appraisal guidance
Slide sheets for repositioning or moving a person on or from a bed: Late Stage AssessmentHealth technology evaluation
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]Technology appraisal guidanceTBC
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]Technology appraisal guidance
Somapacitan for treating growth hormone deficiency in children [ID6178]Technology appraisal guidanceTBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]Technology appraisal guidance
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632Technology appraisal guidanceTBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]Technology appraisal guidance
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)Medical technologies guidanceTBC
Sparsentan for treating primary IgA nephropathy [ID6308]Technology appraisal guidance
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Technology appraisal guidance
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]Technology appraisal guidanceTBC
Spesolimab for treating generalised pustular psoriasis flares [ID3963]Technology appraisal guidance
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]Technology appraisal guidanceTBC
Surgical vessel sealing systems (MT798)Medical technologies guidanceTBC
Suspected cancer updateQuality standardTBC
Suspected sepsis: recognition, diagnosis and early managementNICE guidelineTBC
Suspected sepsis: recognition, diagnosis and early managementNICE guideline
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]Technology appraisal guidanceTBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]Technology appraisal guidance
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments ID5082Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All